Epigenetic pharmaceuticals hold the promise of using cell-based regeneration to revolutionize wound healing treatment. Histone acetylation and deacetylation conducts an intriguing way that influences the fate of stem cells. In this context, we used pharmacological manipulation to coordinate histone acetylation in stem cells. When HDACs expression reduced or silenced using HDAC inhibitors, such as Suberoylanilide hydroxamic acid (SAHA), a spectacular transformation occurred at the cellular and the molecular levels. In our study, we used adipose-derived stem cells which received consecutive SAHA treatment for 72 hours. No change in the cell viability could be noticed at the studied concentrations. On the other hand, a decrease in the protein expression of histone deacetylases at 1000 nM was found. The cell proliferation marker (Ki-67) was increased after SAHA treatment compared to the vehicle as shown by immunofluorescence staining. The expression of CCND1 gene expression was upregulated, while the protein expression of the proliferating cell nuclear antigen was downregulated. Alternatively, microarray analysis revealed that CDKN1A and MDM2 genes were upregulated under the influence of SAHA. On the other hand, the mass spectrometry pathway enrichment analysis showed that cell cycle, ATP-dependent chromatin remodeling and DNA are among the regulated pathways. This study suggested that SAHA as pharmaco-epigenetic agent might alter ADSCs determination through coordinated biological processes.